PDL BioPharma (PDLI) Tops Q4 EPS by 12c, Beats on Revenues
Tweet
Share
E-mailGet Alerts PDLI Hot Sheet
Price: $2.47 --0%
Financial Fact:
Income tax expense: 14.4M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Income tax expense: 14.4M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Note: EPS may not be comparable
PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68 million versus the consensus estimate of $45.3 million.
For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
